Letter

A/H1N1 flu pandemic

Antiviral drugs: distinguish treatment from prophylaxis

BMJ 2009; 339 doi: 10.1136/bmj.b3620 (Published 8 September 2009)
Cite this as: BMJ 2009;339:b3620

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Benjamin J Cowling, assistant professor1,
  2. Sophia Ng, doctoral student1,
  3. Ira M Longini Jr, professor2
  1. 1School of Public Health, University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China
  2. 2Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
  1. bcowling{at}hku.hk

    Shun-Shin and colleagues provide a timely review of the effectiveness of neuraminidase inhibitors for treatment and chemoprophylaxis of flu virus infections.1 As the pandemic A/H1N1 flu virus seems to have remained susceptible in vitro to neuraminidase inhibitors we expect that effectiveness against the pandemic virus would be similar to that against seasonal …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular